September 2022 Microbial Metabolites Orchestrate a Distinct Multi-Tiered Regulatory Network in the Intestinal Epithelium That Directs P-Glycoprotein Expression "P-glycoprotein (P-gp) is a key component of the intestinal We now aim to determine the molecular mechanism by which this functional microbiome output regulates These findings shed light on a sophisticated signaling network directed by intestinal microbial metabolites Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 Endothelin-1 Stimulates PAI-1 Protein Expression via Dual Transactivation Pathway Dependent the expression of plasminogen activator inhibitor type<br />1 (PAI-1) which leads to cardiovascular disorders The purpose of this study was to evaluate the role of dual transactivation of EGF and TGF-β receptors of G protein-coupled receptor (GPCR) signaling, the functions of ROCK and PLC were investigated in dual Read more at the source #DrGPCR #GPCR #IndustryNews

activation of phospholipase C (PLC) is thought to have a key role in the cardiomyocyte response to several different PLC activity results in the generation of diacylglycerol and inositol trisphosphate, which are downstream In this article, we describe the signal transduction elements that regulate PLC gene expression. The discussion is focused on the norepinephrine- α1-adrenoceptor signaling pathway and downstream signaling Read more at the source #DrGPCR #GPCR #IndustryNews

The 3rd edition of the Dr. GPCR Summit is between October 10th to the 16th! ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr

We're very excited to announce the next episode of the Dr. GPCR podcast! 🥁 Drum rolls, please! Our guest is the wonderful Dr. Rosie Dawaliby! Watch the full video with a Dr. GPCR Ecosystem paid membership ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-84-with-rosie-dawaliby #gpcr #drgpcr

💻Did you know that Dr. GPCR is much more than a podcast? Come check out the brand new Dr. We have #GPCR News, Learning Center, Events, and more to discover! Learn More HERE ➡️ https://www.ecosystem.drgpcr.com/learning-center #gpcr #drgpcr

Today, InterAx Biotech is pleased to announce that Carola Weiss has joined the company as VP Business Development Carola Weiss ’ professional career brings deep expertise in business development, marketing & sales, Read more at the source #DrGPCR #GPCR #IndustryNews

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)." Read more at the source #DrGPCR #GPCR #IndustryNews

January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines "Collaborative efforts aim to accelerate drug discovery novel small molecule candidates across oncology and immunology, leveraging Exscientia ’s end-to-end AI-driven Sanofi in-licensed Exscientia ’s novel bispecific small molecule candidate capable of targeting two distinct Read more at the source #DrGPCR #GPCR #IndustryNews

of protein structures in the discovery and development of novel drug candidates. Professor Deane is one of the UK’s most accomplished bioinformaticians. Prior to this, Professor Deane was Deputy Executive Chair of the Engineering and Physical Sciences Research She has played an active role during the COVID-19 pandemic as the UKRI’s COVID Response Director, and R ead more at the source #DrGPCR #GPCR #IndustryNews

February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR discovery. decades—but the two-year-old biotech believes the area is still ripe for development, and it now has to oil drilling around the world." Read more at the source #DrGPCR #GPCR #IndustryNews

📢 Did you know that this 3rd Edition of the Dr. ➡️ https://www.ecosystem.drgpcr.com/ #gpcr #drgpcr

August 2022 "The atypical chemokine receptor 1 (ACKR1) was discovered on erythrocytes as the Duffy blood group antigen ( Cutbush et al., 1950 ), also called Duffy-antigen/receptor for chemokines, or DARC ( Erythrocytes are terminally differentiated anuclear cells with no transcription and limited translation Pruenster et al., 2009 ; Thiriot et al., 2017 ), including those lining bone marrow (BM) sinusoids ( Duchene This well-established, distinctive pattern of cell expression has been directly challenged by a publication

August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program In addition, Structure Therapeutics has completed dosing in a single ascending dose (SAD) Phase 1 study of its lead type 2 diabetes and obesity program, GSBR-1290." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "Join Us in Boston for Discovery On Target 2022! Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents Read more at the source #DrGPCR #GPCR #IndustryNews

extracellular regulated protein kinases (ERK1/2), signal transducer and activator of transcription 3 (STAT3), cyclic TGR5 is widely distributed in the brain, lung, heart, liver, spleen, pancreas, kidney, stomach, jejunum Several recent studies have demonstrated that TGR5 exerts inconsistent effects in different cancer cells In this review, we discuss both the ‘friend’ and ‘foe’ features of TGR5 by summarizing its tumor-suppressing Read more at the source #DrGPCR #GPCR #IndustryNews

position as Scientific co-founder LASEREDD Therapeutics " Ross Bathgate Read more at the source #DrGPCR

June 2022 "We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic areas, including Oncology, Infectious Diseases, Immunology and Critical Care. He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental New Drug Applications (SNDA).

June 2022 Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) These data will be shared as an oral presentation by Ron S. ., University of California , San Diego and Rady Children's Hospital, San Diego on June 13 from 11:00 Read more at the source #DrGPCR #GPCR #IndustryNews

May 2022 "We are thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 #ForbesUnder30 #ArcoScreen #sciences #EPFL" Read more at the source #DrGPCR #GPCR #IndustryNews

Discovering new ways to ameliorate pathological angiogenesis may bypass organ fibrosis. The cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS)-stimulator of exists as to whether cGAS/STING activation exacerbates inflammation and tissue injury or mitigates damage Meanwhile, cGAS deletion upregulated profibrotic Yes-associated protein (YAP) signaling in endothelial Read more at the source #DrGPCR #GPCR #IndustryNews

The second messenger cyclic adenosine monophosphate (cAMP) is a key mediator in many GPCR signaling pathways The GloSensor™ cAMP assay enables real-time monitoring of signaling downstream of many GPCRs. Here, we describe the temperature sensitivity and reversibility of the GloSensor™ cAMP assay, and which We also present a detailed protocol for monitoring cAMP levels in live cells expressing endogenous or discovery" Read more at the source #DrGPCR #GPCR #IndustryNews

Some studies have suggested that VAMP2 may be involved in regulating dopamine D2 receptor signaling by Through developing a high-resolution method, Hao Chen et al. directly visualized the fusion of vesicles and also this different molecular codes will be modulated by different opioids, either endogenous or exogenous, promoving a differential organization of MOR receptors in vesicles with different proteins Jurado, S., D. Goswami, Y. Zhang, A.J.M. Molina, T.C. Südhof, and R.C. Malenka. 2013.

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain " — Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics , a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating

Next on the Dr. GPCR Podcast, we have none other than Dr. Marta Filizola! https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr #drgpcr #podcast

We have cloned and characterized SK and SKR genes in the D. armandi and carried out bioinformatics predictions on the basis of the deduced amino acid sequences, which are very similar to those from Dendroctonus significant changes in different developmental stages, tissues, and between starvation and following Additionally, RNA-interference (RNAi) using double-stranded RNA to knock down SK and SKR reduced the parallel, injection of SK caused a significant reduction in body weight and increase in mortality of D.